Form 4: Bausch Health Director Richard Mulligan Reports Share Acquisition and Disposal

Director Richard Mulligan reports acquisition of 54,347 common shares and disposal of 155,616 common shares of Bausch Health Companies Inc.

Summary

• Richard Mulligan, a director of Bausch Health Companies Inc., filed a Form 4 detailing changes in beneficial ownership.
• On May 16, 2025, Mulligan acquired 54,347 common shares at $0 and disposed of 155,616 common shares.
• Following these transactions, Mulligan beneficially owns 155,616 common shares.
• The acquisition represents an award of restricted share units (RSUs) granted to non-employee directors with a grant date value of $250,000.
• The RSUs vest immediately prior to the Issuer's next Annual Meeting of Shareholders and are settled in common shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing primarily reports routine transactions related to director compensation. The disposal of shares could raise minor concerns, but the RSU grant offsets this.

Positives

• The acquisition of RSUs indicates continued director alignment with shareholder interests.

Negatives

• The disposal of 155,616 common shares could be interpreted negatively by the market, although it may be related to tax obligations or portfolio rebalancing.

Risks

• Market reaction to the reported disposal of shares could negatively impact the stock price.

Future Outlook

The RSUs will vest immediately prior to the Issuer's next Annual Meeting of Shareholders and are settled in common shares.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Director compensation packages often include RSUs to align executive interests with shareholder value, a common practice among publicly traded companies like Bausch Health.
• The vesting schedule of RSUs, typically tied to continued service or performance milestones, is a standard feature in executive compensation plans, similar to those at comparable companies such as Valeant or Allergan (prior to its acquisition).

Stakeholder Impact

• Shareholders may be interested in the director's transactions as an indicator of confidence in the company's future prospects.

Next Steps

• Monitor future filings for further changes in beneficial ownership.
• Track the vesting and settlement of the RSUs.

Key Dates

Keywords

Bausch Health, Richard Mulligan, Form 4, Beneficial Ownership, Director, RSU, Shares, Acquisition, Disposal